

IMAGION BIOSYSTEMS LIMITED

ASX: IBX

18 July 2025

Update to Notification Regarding Unquoted Securities

Imagion Biosystems (ASX: IBX) (**Company** or **Imagion**), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, advises that due to an administrative error the exercise price and expiry date of one of the tranches of options listed was incorrect. The exercise price and expiry date of the new class of options labelled OPTIONS EXPIRING 29 MAY 2023 EX \$0.024, should be \$0.019 (1.9 cents) and 29 May 2028, respectively.

Authorisation & Additional Information

This announcement was authorised by the Company Secretary of Imagion Biosystems Limited.

— ENDS —

About Imagion Biosystems

Imagion Biosystems is developing a new non-radioactive and precision diagnostic molecular imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible.

For more information, visit <https://imaginationbiosystems.com/investor-hub/>

Media & Investor Relations:

Email: info@imaginationbio.com

AU: +61 3 9692 7222

Imagion Biosystems Limited

ASX: IBX ACN 616 305 027

Suite 2, Level 11 385 Bourke Street Melbourne VIC 3000

<http://www.imaginationbiosystems.com/> | investor@imaginationbio.com

